Expression Of Survivin And Bcl-Xl Protein In Cutaneous T-Cell Lymphoma

Objietive: Our purpose is to investigate the expression of survivin and bcl-xl in different clinical stage of Cutaneous T-cell lymphoma(CTCL),to evaluate the clinical value of survivin and bcl-xl in the diagnosis ,treatment and prognosis of CTCL as well as their role during the progression of CTCL.Methods: We designed a immunohistochemical assay to study the expression of survivin and bcl-xl in 10 normal skins and 30 CTCL,then compared the results with relevant clinical and pathologic data.Results: Survivin protein was undetectable in all normal skins, while it was expressed in 40%(2/5) of the patch-stage,in 75%(12/16) of the plaque-stage and in 77.8%(7/9) of the tumor-stage.The expression of survivin protein in CTCL was significantly higher than in normal skins(p<0.05).The expression of survivin protein in tumor-stage was significantly higher than in patch-stage(p<0.05).Bcl-xl protein was undetectable in all normal skins too,while it was expressed in 60%(3/5) of the patch-stage,in 68.8%(11/16)of the plaque-stage and in 88.9%(8/9)of the tumor-stage. The expression of bcl-xl protein in CTCL was significantly higher than in normal skins(p<0.05).The expression of bcl-xl protein in tumor-stage was significantly higher than in patch-stage(p<0.05).In CTCL survivin expression was strongly related with bcl-xl expression(r=0.592,p<0.05).Conclusions: The survivin and bcl-xl are expressed in a vast majority of CTCL,The expression of survivin and bcl-xl protein in tumor-stage was highest in three stage, In CTCL survivin expression was strongly related with bcl-xl expression, anti-apoptosis together, take a important role during the progression of CTCL. Survivin and bcl-xl can be regarded as molecular marker of CTCL lesions, also can be an ideal therapeutic target for cancer treatment.